Generics drive U.S. drug sales growth
Unbranded drug sales grew 22 percent in 2006, driving U.S. prescription drug sales up 8.3 percent to $274.9 billion during the year. According to IMS Health, which released annual sales figures March 8, strong generic sales were driven by Teva's simvastatin (Zocor), which generated $911 million in sales, and Apotex's generic clopidogrel (Plavix), which brought in $902 million. Medicare Part D was the other major sales growth driver, with prescriptions dispensed through the federal program accounting for 17 percent of retail scripts by the end of the year, IMS says. Biotech segment sales jumped 20 percent to $40.3 billion, driven by Amgen's Aranesp (up 42 percent to $3.9 billion), Enbrel (up 12 percent to $3.1 billion) and Neulasta (up 28 percent to $2.9 billion). Total U.S. prescription volume grew 4.6 percent in 2006 compared to 3.3 percent growth in 2005...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.